Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Autoimmune CRMP5 neuropathy phenotype and outcome defined from 105 cases.

Neurology - 9 Jan 2018

Dubey Divyanshu, Lennon Vanda A, Gadoth Avi, Pittock Sean J, Flanagan Eoin P, Schmeling John E, McKeon Andrew, Klein Christopher J

Abstract excerpt

OBJECTIVE: To establish the phenotype and clinical outcomes of collapsin response-mediator protein-5 (CRMP5) autoimmune neuropathy in comparison with anti-neuronal nuclear antibody type 1 (ANNA1)-immunoglobulin G (IgG) neuropathy. METHODS: Patients with CRMP5-IgG and/or ANNA1-IgGs were identified in our service-line testing, and medical records were reviewed. RESULTS: One hundred five patients with CRMP5-IgG...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Antinuclear
Share to Antibodies, Neoplasm

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Autoimmune Diseases of the Nervous System

Share to Hydrolases

Share to Immunoglobulin G

Share to Immunotherapy

Share to Microtubule-Associated Proteins

Share to Peripheral Nervous System Diseases

Source

Identifiers

PMID: 29222126
DOI: 10.1212/WNL.0000000000004803

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Autoimmune CRMP5 neuropathy phenotype and outcome defined from 105 cases.PMID 29222126Read ↗

Phenotypic presentations of paraneoplastic neuropathies associated with MAP1B-IgGSemantic proximity Read ↗

Mechanism, and treatment of anti-CV2/CRMP5 autoimmune painSemantic proximity Read ↗

Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathiesSemantic proximity Read ↗

Paraneoplastic isolated myelopathy: clinical course and neuroimaging clues.Semantic proximity Read ↗

Anti-neurofascin-155 antibody mediated a distinct phenotype of chronic inflammatory demyelinating polyradiculoneuropathy.Semantic proximity Read ↗

Antimelanoma Differentiation-associated Gene 5 Antibody: Expanding the Clinical Spectrum in North American Patients with Dermatomyositis.Semantic proximity Read ↗

Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg.Semantic proximity Read ↗

Clinical phenotype and prognostic determinants of spontaneous pneumomediastinum in anti-MDA5 antibody-positive dermatomyositis.Semantic proximity Read ↗

Analysis of 977 Long COVID Patients Reveals Prevalent Neuropathy and Association with Anti-Ganglioside AntibodiesSemantic proximity Read ↗

Expanded phenotypes and outcomes among 256 LGI1/CASPR2-IgG-positive patients.Semantic proximity Read ↗

Anti-Plexin-D1 Seropositive Small Fiber Neuropathy: Clinical Phenotype, Demographics, and Literature Review.Semantic proximity Read ↗

CIDP With and Without Monoclonal Gammopathy of Undetermined Significance (MGUS): Comparison of Clinical Phenotype, Diagnostic Features, and Treatment Response.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.